

Alain Matagne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039893/publications.pdf>

Version: 2024-02-01

16
papers

2,883
citations

623574

14
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

2242
citing authors

#	ARTICLE	IF	CITATIONS
1	The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9861-9866.	3.3	1,431
2	Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology, 1998, 353, 191-206.	1.7	432
3	Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties. European Journal of Pharmacology, 2011, 664, 36-44.	1.7	198
4	SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology, 2008, 54, 715-720.	2.0	151
5	Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia, 2016, 57, 538-548.	2.6	137
6	Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Research, 1998, 31, 59-71.	0.8	116
7	Benefit of combination therapy in epilepsy: A review of the preclinical evidence with levetiracetam. Epilepsia, 2009, 50, 387-397.	2.6	97
8	Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia, 2009, 50, 1729-1740.	2.6	97
9	Use of epileptic animals for adverse effect testing. Epilepsy Research, 2002, 50, 55-65.	0.8	45
10	Low potency and limited efficacy of antiepileptic drugs in the mouse 6Hz corneal kindling model. Epilepsy Research, 2014, 108, 675-683.	0.8	43
11	Genetic background of mice strongly influences treatment resistance in the 6ÂHz seizure model. Epilepsia, 2015, 56, 310-318.	2.6	42
12	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 11-20.	1.3	27
13	Profile of the new pyrrolidone derivative seletacetam (ucb 44212) in animal models of epilepsy. European Journal of Pharmacology, 2009, 614, 30-37.	1.7	24
14	Anticonvulsant and antiepileptogenic effects of system xc ⁻ inactivation in chronic epilepsy models. Epilepsia, 2019, 60, 1412-1423.	2.6	20
15	Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. Epilepsy and Behavior, 2015, 49, 55-60.	0.9	13
16	11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice. Neuropharmacology, 2011, 60, 1098-1108.	2.0	10